Quick access to up-to-date company information.
New Data Analyses on Investigational Tiotropium/Olodaterol Respimat® Showed Greater Lung Function Improvement Compared to Tiotropium and Olodaterol Alone
BIPI Statement On The Update To The ATS/ERS/JRS/ALAT Clinical Practice Guidelines For The Treatment Of Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim Presents New Data and Analyses Reinforcing the Safety and Efficacy of OFEV® (nintedanib) Capsules
Boehringer Ingelheim Awards Grants to Support Innovative Research on Genetic Markers in Atrial Fibrillation and Treatment Adherence with Electronic Alert Program
Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO with new data including presentation of Gilotrif® (afatinib) overall survival results for squamous cell carcinoma of the lung
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877